Krishna Institute of Medical Sciences Limited announced its unaudited standalone and consolidated financial results for the quarter ended September 30, 2025 (Q2 2025). The results were reviewed by auditors, with conclusions based on available information and other auditor reports for subsidiaries and associates. No matters were identified that would suggest material misstatement in the financial results.
Standalone Financial Results Review
The standalone financial results of Krishna Institute of Medical Sciences Limited for Q2 2025 have been reviewed by the company’s Board of Directors. The review, conducted by independent auditors, found no indication of material misstatement in the presented financial statements. The audit was conducted in accordance with established standards, focusing on obtaining moderate assurance regarding the accuracy and reliability of the reported figures.
Consolidated Financial Results Overview
The consolidated results include Krishna Institute of Medical Sciences Limited (“Holding Company”), its subsidiaries (“the Group”), and its associate. The consolidated financial results have also been reviewed with independent auditor reports received from subsidiary auditors as well.
Subsidiary Financial Highlights
The unaudited interim financial results of three subsidiaries include total assets of Rs. 3,042 million as of September 30, 2025. Total revenues for these subsidiaries were Rs. 248 million for the quarter and Rs. 471 million year-to-date. The total net loss after tax was Rs. 51 million and Rs. 108 million, for the quarter and year-to-date respectively.
Associate Performance
One associate’s unaudited interim financial results include the Group’s share of net loss of Rs. Nil for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025.
Source: BSE
